N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease

NCT07741071 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

270

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer Disease (AD)

Interventions

DIETARY_SUPPLEMENT: Nicotinamide Riboside (NR)
OTHER: Palacebo

Sponsor

Haukeland University Hospital